🔗 Share this article

Given that the United States proceeds with unprecedented adjustments to its vaccination schedules, one figure appears somewhat surprisingly: Høeg, an American of Danish descent sports medicine doctor and epidemiologist who first made her name by expressing skepticism about coronavirus shots in the global health crisis and has concentrated on potential fatalities after COVID-19 immunization in her recent tenure at the FDA.

Scheduled Changes to Pediatric Immunization Program

Agency leaders were set to reveal sweeping changes to the pediatric vaccination calendar recently, synchronizing the US with Denmark’s national calendar, according to reports – a significant shift that would put the US out of step with much of the world with no evidence for benefit. This reveal has been postponed until the next year.

Rather than the director of the vaccine center, Dr. Høeg is scheduled to present at the event. She was recently named interim head of the FDA’s CDER, the fifth person to run the division this year.

Consolidating Power at the Agency

Høeg's temporary position might represent a tighter collaboration between the pharmaceutical and biologics centers as Høeg and Dr. Prasad strengthen their influence at the regulatory agency – and it points to a greater focus upon reevaluating previously authorized immunizations at the FDA.

The new acting director has often pushed for ending specific childhood vaccine recommendations in the US so as to align more in line with the Danish model, a society with nationalized medicine and a citizenry about the size of Wisconsin’s.

So far statements, she has kept her attention on vaccination policy – traditionally the responsibility of Dr. Prasad, director of the FDA’s CBER – instead of pharmaceutical oversight.

Questions Over Expertise

Høeg has little discernible background in pharmaceutical research, regulation or management, which has been typical for former directors of the biologics center. She has been employed at the FDA as a top consultant to the commissioner and the vaccine center since earlier this year.

“She doesn’t seem to have the requisite experience” for leading the drug-regulation department, remarked a neurologist and psychiatrist. “She has not conducted a clinical trial. She is not versed in leading a sizeable institution. She has no expertise in drug approvals.”

Former heads of the center would “be deeply familiar with laws and regulations and the research of pharmaceutical innovation”, noted Dr. Janet Woodcock. “Frankly, she has not acquired the type of experience that prior appointees who headed CBER have had.”

The drug center has an enormous portfolio at the agency, she emphasized.

“Many people just focuses on the innovative therapies, but the generic drug division clears thousands of generic medications. There is also a biosimilars division, over-the-counter program and other areas, and each of these have to be supervised,” Dr. Woodcock noted. “The thing you overlook, that is precisely what that I always told people is going to come back to haunt you.”

Additionally, a major management element to the position, which supervises more than 5,000 staff members. “It’s a huge administrative position, if you perform it correctly,” she concluded.

Agency Reaction and Disputed Programs

In response to concerns about Dr. Høeg's fitness for the role and whether this selection represents increased cooperation among FDA leaders on immunizations, a representative responded that the “questions stem from inaccurate assumptions”.

“Her resume is consistent with the responsibilities of her job,” the spokesperson explained, citing the time Høeg spent advising the FDA commissioner on “drug safety and approval science, including computational safety modeling and shot safety tracking”.

As acting director, Høeg inherits the agency head's new expedited review system, a controversial expedited medication authorization process that allegedly concerned her former heads. “How are these therapies being picked for this voucher program? Who is making the calls?” Howard questioned. “There’s a lot of confidentiality happening at the FDA right now.”

Overall, he remarked, “the agency looks to be trending towards laxer rules of pharmaceuticals, with the exception of immunizations.”

Public History on Immunizations

Concerning vaccines, Dr. Høeg has a more established, if troubling, track record, Howard said. She released a study using unconfirmed crowd-sourced reports to assess the rate of myocarditis after COVID-19 vaccination. She counseled the Florida surgeon general Dr. Joseph Ladapo, who allegedly have modified findings to indicate COVID-19 vaccinations are riskier than they are.

Included in her “wish list” for the new government featured altering rules for recently developed shots and ending “unnecessary” immunizations, she remarked post-election on a audio program. At the FDA, Høeg has reportedly floated the idea of barring teenage boys from obtaining COVID-19 vaccinations.

“She is an complete true believer who starts off with her beliefs and works backwards to accommodate the evidence in a highly misleading, fraudulent way,” Dr. Howard stated.

Taking Control and a “Push for Payback”

Høeg aligned with other dissenters, {like|